{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464207919
| IUPAC_name = 1-(3-Cyano-3,3-diphenyl-propyl)-4-(1-piperidyl)piperidine-4-carboxamide
| image = Piritramide2DACS.svg
| width = 130px
| image2 = Piritramide-xtal-1977-ball-and-stick.png
| width2 = 230px

<!--Clinical data-->
| tradename = Dipidolor
| Drugs.com = {{drugs.com|international|piritramide}}
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category = No teratogenic effects in preclinical studies; but, as with other opioids it may cause reversible adverse effects in the newborn. 
| legal_AU = S8
| legal_CA = Schedule I
| legal_DE = Anlage III
| legal_US = Schedule I
| routes_of_administration = Oral, [[Intramuscular injection|IM]], [[Intravenous therapy|IV]]

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 95%<ref name = deranaes>{{cite journal|last=Jage|first=J|author2=Laufenberg-Feldmann, R |author3=Heid, F |title=Medikamente zur postoperativen Schmerztherapie: Bewährtes und Neues|trans_title=Drugs for postoperative analgesia: routine and new aspects: Part 2: opioids, ketamine and gabapentinoids|journal=Der Anaesthesist|date=May 2008|volume=57|issue=5|pages=491–8|doi=10.1007/s00101-008-1327-9|pmid=18409073|language=German}}</ref>
| metabolism = Liver
| elimination_half-life = 4-10 hours (acute dosing), 17.4 hours (chronic dosing)
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 302-41-0
| ATC_prefix = N02
| ATC_suffix = AC03
| ATC_supplemental =  
| PubChem = 9331
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8967
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4RP92LYZ2F
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07288
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 559288

<!--Chemical data-->
| C=27 | H=34 | N=4 | O=1 
| molecular_weight = 430.585 g/mol
| smiles = N#CC(C1=CC=CC=C1)(CCN2CCC(N3CCCCC3)(CC2)C(N)=O)C4=CC=CC=C4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C27H34N4O/c28-22-26(23-10-4-1-5-11-23,24-12-6-2-7-13-24)14-19-30-20-15-27(16-21-30,25(29)32)31-17-8-3-9-18-31/h1-2,4-7,10-13H,3,8-9,14-21H2,(H2,29,32)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IHEHEFLXQFOQJO-UHFFFAOYSA-N
}}

'''Piritramide''' ('''R-3365''', trade names '''Dipidolor''', '''Piridolan''', '''Pirium''' and others) is a synthetic [[opioid]] [[analgesic]] (narcotic painkiller) that is marketed in certain [[Europe]]an countries including: [[Austria]], [[Belgium]], [[Czech Republic]], [[Germany]] and the [[Netherlands]].<ref name = MD>{{cite web|title=Piritramide|work=Martindale: The Complete Drug Reference|publisher=Pharmaceutical Press|accessdate=22 April 2014|date=23 September 2011|editor=Brayfield, A|url=http://www.medicinescomplete.com/mc/martindale/current/6259-x.htm}}</ref> It comes in free form, is about 0.75x times as potent as [[morphine]] and is given [[parenterally]] (by injection) for the treatment of severe pain.<ref name = MD/><ref>{{cite journal|last=Kay|first=B|title=A clinical investigation of piritramide in the treatment of postoperative pain.|journal=British Journal of Anaesthesia|date=December 1971|volume=43|issue=12|pages=1167–71|doi=10.1093/bja/43.12.1167|pmid=4945251}}</ref> Nausea, vomiting, respiratory depression and constipation are believed to be less frequent with piritramide than with [[morphine]] (the gold standard opioid against which other opioids are compared and contrasted), and it produces more rapid-onset analgesia (pain relief) when compared to morphine and [[pethidine]]. After intravenous administration the onset of analgesia is as little as 1–2 minutes, which may be related to its great [[lipophilicity]].<ref name = SPC>{{cite web|title=FACHINFORMATION (Zusammenfassung der Merkmale des Arzneimittels)|trans_title=PROFESSIONAL INFORMATION (Summary of Product Characteristics)|work=Janssen|publisher=Janssen - Cilag Pharma GmbH|format=PDF|url=http://www.janssen-medinfo.at/sites/janssen_medinfo_at/themes/medinfo_at/images/Dipidolor_FI_20131206.pdf|accessdate=9 April 2014|date=November 2013}}</ref> The analgesic and sedative effects of piritramide are believed to be potentiated with phenothiazines and its emetic (nausea/vomiting-inducing) effects are suppressed.<ref name = SPC/> The [[volume of distribution]] is 0.7-1 L/kg after a single dose, 4.7-6 L/kg after steady-state concentrations are achieved and up to 11.1 L/kg after prolonged dosing.<ref name = SPC/>

Piritramide was developed and patented in Belgium, at Janssen, in 1960.  It is part of an eponymous two-member class of opioids in clinical use with the other being [[bezitramide]] (Burgodin).  The closest chemical and structural relatives of piritramide in clinical use include the [[diphenoxylate]] family, [[fentanyl]] (both Janssen discoveries) and somewhat more distantly [[alphaprodine]].

Not being in clinical use in the United States, it is a Schedule I Narcotic controlled substance with a DEA ACSCN of 9642 and manufacturing quota of zero.<ref>http://www.deadiversion.usdoj.gov/fed_regs/quotas/2013/fr0620.htm</ref>

==See also==
*[[Diphenoxylate]]
*[[Bezitramide]]
*[[Pipamperone]]

==References==
{{Reflist|2}}


{{Analgesics}}
{{Opioidergics}}

[[Category:Opioids]]
[[Category:Piperidines]]
[[Category:Carboxamides]]
[[Category:Nitriles]]
[[Category:Mu-opioid agonists]]
[[Category:Janssen Pharmaceutica]]
[[Category:Belgian inventions]]